GSK completes $3 billion acquisition of Human Genome
LONDON (Reuters) - GlaxoSmithKline has completed its $3 billion acquisition of long-time biotech partner Human Genome Sciences, after buying all the outstanding shares for $14.25 each in cash, Britain's biggest drugmaker said on Friday.
The deal secures it full rights to recently launched lupus drug Benlysta and other experimental medicines.
(Reporting by Ben Hirschler)
Thousands line up to say goodbye to Nelson Mandela, whose body is lying in state in Pretoria. Slideshow
WASHINGTON - U.S. small business sentiment bounced back from a seven-month low in November, with owners setting their sights on creating more jobs and expanding operations.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.